At present, PD-L1 is the only biomarker used routinely in clinical practice to guide immunotherapy treatment decisions in NSCLC, with many oncological guidelines now suggesting a chemotherapy-sparing treatment strategy for high PD-L1 expressing disease. This evidence concerns the gene CD274 and non-small cell lung carcinoma.